GRI Bio, Inc.
Develops NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
GRI | US
Overview
Corporate Details
- ISIN(s):
- US3622AW4030 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2223 AVENIDA DE LA PLAYA, 92037 LA JOLLA
- Website:
- https://www.gribio.com/
- Sector:
- Manufacturing
Description
GRI Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapies for inflammatory, fibrotic, and autoimmune diseases. The company's primary focus is on advancing its pipeline of Natural Killer T (NKT) cell modulators. This therapeutic strategy targets the initial stages of the inflammatory cascade, aiming to interrupt disease progression and fundamentally alter the treatment of these conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GRI Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GRI Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GRI Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
